S R Kanduri1, W Cheungpasitporn1, C Thongprayoon2, T Bathini3, K Kovvuru1, V Garla4, J Medaura1, P Vaitla1, K B Kashani2,5. 1. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216. 2. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905. 3. Department of Internal Medicine, University of Arizona, Tucson, AZ 85701. 4. Division of Endocrinology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216. 5. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Abstract
BACKGROUND: While acute kidney injury (AKI) is commonly reported following hematopoietic stem cell transplant (HCT), the incidence and impact of AKI on mortality among patients undergoing HCT are not well described. We conducted this systematic review to assess the incidence and impact of AKI on mortality risk among patients undergoing HCT. METHODS: Ovid MEDLINE, EMBASE and the Cochrane Databases were searched from database inceptions through August 2019 to identify studies assessing the incidence of AKI and mortality risk among adult patients who developed AKI following HCT. Random-effects and generic inverse variance method of DerSimonian-Laird were used to combine the effect estimates obtained from individual studies. RESULTS: We included 36 cohort studies with a total of 5144 patients undergoing HCT. Overall, the pooled estimated incidence of AKI and severe AKI (AKI Stage III) were 55.1% (95% confidence interval (CI) 46.6-63.3%) and 8.3% (95% CI 6.0-11.4%), respectively. The pooled estimated incidence of AKI using contemporary AKI definitions (RIFLE, AKIN and KDIGO criteria) was 49.8% (95% CI 41.6-58.1%). There was no significant correlation between study year and the incidence of AKI (P = 0.12) or severe AKI (P = 0.97). The pooled odds ratios of 3-month mortality and 3-year mortality among patients undergoing HCT with AKI were 3.05 (95% CI 2.07-4.49) and 2.23 (95% CI 1.06-4.73), respectively. CONCLUSION: The incidence of AKI among patients who undergo HCT remains high, and it has not changed over the years despite advances in medicine. AKI after HCT is associated with increased short- and long-term mortality.
BACKGROUND: While acute kidney injury (AKI) is commonly reported following hematopoietic stem cell transplant (HCT), the incidence and impact of AKI on mortality among patients undergoing HCT are not well described. We conducted this systematic review to assess the incidence and impact of AKI on mortality risk among patients undergoing HCT. METHODS: Ovid MEDLINE, EMBASE and the Cochrane Databases were searched from database inceptions through August 2019 to identify studies assessing the incidence of AKI and mortality risk among adult patients who developed AKI following HCT. Random-effects and generic inverse variance method of DerSimonian-Laird were used to combine the effect estimates obtained from individual studies. RESULTS: We included 36 cohort studies with a total of 5144 patients undergoing HCT. Overall, the pooled estimated incidence of AKI and severe AKI (AKI Stage III) were 55.1% (95% confidence interval (CI) 46.6-63.3%) and 8.3% (95% CI 6.0-11.4%), respectively. The pooled estimated incidence of AKI using contemporary AKI definitions (RIFLE, AKIN and KDIGO criteria) was 49.8% (95% CI 41.6-58.1%). There was no significant correlation between study year and the incidence of AKI (P = 0.12) or severe AKI (P = 0.97). The pooled odds ratios of 3-month mortality and 3-year mortality among patients undergoing HCT with AKI were 3.05 (95% CI 2.07-4.49) and 2.23 (95% CI 1.06-4.73), respectively. CONCLUSION: The incidence of AKI among patients who undergo HCT remains high, and it has not changed over the years despite advances in medicine. AKI after HCT is associated with increased short- and long-term mortality.
Authors: Imed Helal; Anies Byzun; Jean Philipe Rerolle; Emanuel Morelon; Henri Kreis; Marie France Bruneel-Mamzer Journal: Saudi J Kidney Dis Transpl Date: 2011-05
Authors: Amit Fadia; Liam F Casserly; Vaishali Sanchorawala; David C Seldin; Daniel G Wright; Martha Skinner; Laura M Dember Journal: Kidney Int Date: 2003-05 Impact factor: 10.612
Authors: Jose M Lopez-Novoa; Yaremi Quiros; Laura Vicente; Ana I Morales; Francisco J Lopez-Hernandez Journal: Kidney Int Date: 2010-09-22 Impact factor: 10.612
Authors: Keith M Olsen; Maria I Rudis; Jill A Rebuck; Jill Hara; Dave Gelmont; Ramin Mehdian; Casey Nelson; Mark E Rupp Journal: Crit Care Med Date: 2004-08 Impact factor: 7.598